Changes in Hong Kong stocks | Yaojie Ankang-B (02617) was approved to list nearly 15% of its core product, tengotinib tablets

The Zhitong Finance App learned that Yaojie Ankang-B (02617) opened nearly 15% higher. As of press release, it had risen 14.92% to HK$13.25, with a turnover of HK$11.1896 million.

According to the news, Pharmaceutical Jieankang issued an announcement last night stating that the new class 1 drug Gentel® (tengotinib tablets) independently developed by the company has been conditionally approved for marketing by the State Drug Administration for adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received systemic treatment and FGFR inhibitor treatment in the past and have FGFR2 fusion or rearrangement. The treatment has previously been included by the NMPA as a priority review and breakthrough treatment category. According to reports, this drug is the first innovative drug approved for marketing by Yaojiekang.

The Phase II key clinical study showed that as of December 27, 2025, the median follow-up was 12 months. The objective response rate (ORR) for 50 cases of advanced cholangiocarcinoma was 28.0%, the disease control rate (DCR) was 82.0%, the median progression-free survival (mPFs) was 6.0 months, and the median overall survival (MoS) was 20.7 months. Gentech® has previously obtained “Fast Track Qualification” and “Orphan Drug Certification” from the US FDA, and “Orphan Drug Certification” granted by the European EMA to treat biliary tract cancer.